NEWS
Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy?
2025-11-09
Spyre Therapeutics recently announced positive interim Phase 1 results for its investigational antibody SPY003, showing good tolerability and a long half-life, with plans to advance into Phase 2 studies and ongoing capital-raising efforts supporting continued development. An interesting insight is the company's improved financial performance over the last quarter and nine months, reporting a net loss reduction and a lower basic loss per share compared to the previous year. We will explore...
Spyre Therapeutics Announces Grants of Inducement Awards
2025-11-07
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 19,600 shares of common stock of Spyre to one non
Spyre Therapeutics: Q3 Earnings Snapshot
2025-11-04
WALTHAM, Mass. AP) — Spyre Therapeutics, Inc. SYRE) on Tuesday reported a loss of $11.2 million in its third quarter.
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-04
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA") On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Fu
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
2025-11-04
SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investigational combination therapies for IBD with potential for indication-leading efficacy, safety, and dosing profiles SPY003 expected to advance to the ongoing Part A of the SKYLINE Ph2 platform trial SKYLINE and SKYWAY trials are expected to provide 6 proof-of-conc
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
2025-10-29
WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation Conference - BostonDate: Monday, November 10, 2025Fireside Time: 1
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
2025-10-24
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the ACR Convergence Congress. “We are excited to share follow-up data out to six months from our Phase 1 study of SPY072, our potential first- and best-in-class anti-TL1A
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
2025-10-15
WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the closing of its previously announced underwritten public offering of 17,094,594 shares of its common stock, including the full ex
Spyre Therapeutics (SYRE): Assessing Valuation Following Major Equity Offering and Share Price Surge
2025-10-15
Spyre Therapeutics (SYRE) has just completed a sizable follow-on equity offering, raising $275 million through the sale of nearly 15 million shares of common stock. This move is set to provide fresh capital for the company's ongoing operations and future growth plans. It also prompts investors to consider the implications of share dilution and the evolving market response. See our latest analysis for Spyre Therapeutics. Shares of Spyre Therapeutics have surged this week, with a 1-day share...
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
2025-10-14
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 14,864,865 shares of its common stock at a price to the publ
